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Simple Summary: Improving outcomes in pancreatic cancer is achievable through the accumulation
of marginal gains. There exists evidence of variation and undertreatment in many areas of the
care pathway. By fully realising the existing opportunities, there is the potential for immediate
improvements in outcomes and quality of life.
Abstract: Improving outcomes among patients with resectable pancreatic cancer is one of the greatest
challenges of modern medicine. Major improvements in survival will result from the development of
novel therapies. However, optimising existing pathways, so that patients realise benefits of already
proven treatments, presents a clear opportunity to improve outcomes in the short term. This narrative
review will focus on treatments and interventions where there is a clear evidence base to improve
outcomes in pancreatic cancer, and where there is also evidence of variation and under-treatment.
Avoidance of preoperative biliary drainage, treatment of pancreatic exocrine insufficiency, preha-
biliation and enhanced recovery after surgery, reducing perioperative complications, optimising
opportunities for elderly patients to receive therapy, optimising adjuvant chemotherapy and regular
surveillance after surgery are some of the strategies discussed. Each treatment or pathway change
represents an opportunity for marginal gain. Accumulation of marginal gains can result in consid-
erable benefit to patients. Given that these interventions already have evidence base, they can be
realised quickly and economically.
Keywords: pancreatic cancer; pancreatic exocrine insufficiency; adjuvant chemotherapy; biliary
drainage; prehabilitation; ERAS
1. Introduction
Pancreatic cancer is projected to become the second leading cause of all cancer-related
deaths by 2030 [1,2]. Although surgical resection is the foundation of ‘resectable’ pancreatic
cancer management, alone it is associated with a less than 10% chance of cure [3]. High rates
of perioperative morbidity and mortality, slow or poorly organised pathways to surgery,
suboptimal preoperative management of jaundice, suboptimal use of (neo)adjuvant ther-
apy and failure to address malnutrition all contribute to poor outcomes. It is therefore
unsurprising that there can be a negative attitude and feelings of nihilism when considering
the outlook for these patients.
Wide variations in care and a lack of standardised practice, however, offer an easy
way to improve outcomes in the near future. Pathways to expedite surgery, prescribing
of enzyme therapy, access to adjuvant chemotherapy and tackling frailty are just a few
examples of how care has the potential to be optimised. Optimising an individual aspect
of care represents an opportunity for a marginal gain. Individually, each gain realised
may be relatively minor when observed across an entire patient cohort, but when multiple,
the effect of aggregated marginal gains can be considerable. The aggregation of marginal
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gains was popularised in elite level cycling where its success was clear to see at Olympic
level and major events such as the Tour de France. The principals have been adopted
in healthcare among various patient populations from cancer surgery, stroke recovery,
prehabilitation, cardiac surgery and anaesthesia [4–6]. This narrative review highlights
common failings in the care of pancreatic cancer patients and describes where gains can be
made. The aggregation of these marginal gains could improve outcomes and experience
for a great many patients with resectable pancreatic cancer.
2. Pre-Operative Pathways
At presentation, resectable pancreatic cancer is in an exponential phase of growth and
most primary tumours harbour cells that can metastasise [7]. Enhancing pre-operative
pathways to ensure that patients are treated as quickly as possible and their functional
status is optimised is essential to enabling the delivery of the highest standard of care.
This section will focus on avoidance of pre-operative biliary drainage, prehabilitation, and
optimisation of nutritional status.
2.1. Preoperative Biliary Drainage in Resectable Pancreatic Cancer
The majority of patients with resectable pancreatic cancer present with jaundice.
Historically reluctance to operate in the presence of jaundice was related to concerns
over renal, cardiac and liver dysfunction, coagulopathy and, at the time, high rates of
perioperative morbidity and mortality associated with pancreatic surgery in the absence of
jaundice [8].
Hence, in theory, relief of jaundice by preoperative biliary drainage (PBD) is perceived
to improve these disturbances and prevent postoperative complications, though in practice,
the role and propriety of PBD must be challenged.
The concept of correcting jaundice prior to resection was introduced by A.O. Whipple
through staged PD, initially a cholecystogastrostomy to relieve jaundice followed by resec-
tion once the jaundice was within ‘safe’ limits. This further developed into nonoperative
approaches through percutaneous transhepatic cholangiopathy (PTC) and biliary drainage
in the 1960s and later followed by endoscopic retrograde cholangiopancreatography (ERCP)
in the 1970s [9,10].
For many decades ERCP served both diagnostic and therapeutic purposes. However,
the sensitivity and specificity of CT to diagnose pancreatic cancer has made ERCP, as a
diagnostic tool, obsolete.
The main drawback of PBD is the associated rate of complications. These complica-
tions impair quality of life, can delay or prevent future surgery and are occasionally fatal.
PBD itself requires resource and invariably delays treatment pathways [11,12].
The DROP trial randomised patients to upfront early surgery within 7 days or PBD-
and plastic stent and delayed surgery between 4–6 weeks [13]. This landmark RCT showed
the rate of serious complications at 120 days postoperatively to be far higher in the PBD
group (74 vs. 39%, p < 0.001). This was largely due to drainage-related complications,
cholangitis (26 vs. 2%), pancreatitis (7 vs. 0%) along with the need for change of stent in 30%
of patients. There are also higher rates of perioperative infections, associated with changes
in the biliary microbiome related to PBD [14,15] It is therefore advised that intraoperative
bile cultures are taken and appropriate antibiotic administered to address this higher rate
of complications [16].
Self-expanding metal stents (SEMS) have gained in popularity over plastic stents
based on significantly greater patency and reduction in infectious complications [13,17,18].
The experience of patients undergoing PBD with fully covered SEMS, with a prospective
study which mirrored the protocol of the DROP trial, superimposed the complication rates
of PBD-SEMS over the cohorts within the DROP trial [19]. Though SEMS were associated
with lower rates of complications than plastic stents, the rate remained significantly greater
than upfront surgery (51 vs. 39%). Subsequent meta-analysis confirms advantages of
metal over plastic stents with reduced rates of need for endoscopic reintervention (OR0.3),
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preoperative complications (OR 0.42) and cholangitis (OR 0.09) [20]. However, pancreatitis
is more common (OR 3.6) and, though not reported, post hoc analysis of resection rates
demonstrates a lower resection rate among patients with metal stents (plastic, 147/190 vs.
metal 93/139; Chi square p = 0.04) [19,20]. A more recent network meta-analysis demon-
strated a remarkably high rate of complications with plastic stents (38–93%), a much lower
rate with SEMS (0–15%) whilst data regarding outcomes from percutaneous drainage is
not at extensively reported (31%) [21]. This study also concluded that avoidance of PBD
was associated with the best outcome.
The association between PBD and reduced resection rates was not observed in individ-
ual randomised trials. However, it is logical to associate complications such as pancreatitis
or pathway delays with a reduction in resection rate. Many high-volume centres have
reported that increasing time to surgery reduces resection rates, data confirmed within a
recent systematic review and meta-analysis [22–25]. It may be that this higher resection rate
and avoidance of complications translates into increased survival benefit, when analysed
on an intention to treat basis [26]. This is controversial as some authors have associated
hyperbilirbuinaemia at the time of resection with worse cancer outcomes [27].
Given the many benefits of avoiding PBD, the National Institute for Health and Care
Excellence (NICE) in the United Kingdom, now recommend upfront surgery without PBD
where possible [28].
What remains to be defined is a safe upper limit of bilirubin in terms of safety and
oncologic outcomes and why PBD remains so widely used despite the evidence of harm.
Associated venous resection appears safe in the presence of jaundice, even when levels of
bilirubin exceed 300 µmol/L (>17.5 mg/dL) [29]. It may be assumed that elderly patients
are safer to undergo PBD and surgery rather than upfront surgery but elderly patients
are less likely to tolerate complications of PBD and remain on a surgical pathway than
younger patients.
Numerous studies have established seemingly arbitrary upper limits of bilirubin
at which PBD is indicated [27,30–35]. A common threshold of >250 umol/L is used
and cited by The Guidelines for Perioperative Care for Pancreaticoduodenectomy: En-
hanced Recovery After Surgery (ERAS®) Society Recommendations [36]; Both Sauvanet
and Li et al. reported higher complication rates when surgery was performed with a biliru-
bin of >300 µmol/L [27,37]. However, contrary to this, van der Gaag, quoted a bilirubin
level of ≤300 µmol/L at surgery and demonstrated significantly lower infective complica-
tions, whilst Pamecha et al. showed that a bilirubin level of ≥15 mg/dL (≥265 µmol/L)
was not an independent risk factor for complications [13,38,39].
As stated above, it is the authors experience that surgery, even with venous resection,
can be performed with no difference in complications with bilirubin in excess of 300 µmol/L.
To summarise, there is no clear data that defines an upper limit of bilirubin at which PBD is
indicated. The authors recommend an approach with prospective evaluation of outcomes
and a step wise increase in threshold of bilirubin at which to undertake PBD. Variation in
the rate of increase of bilirubin, the difficulty/time needed to complete staging tests and
other factors such as renal function or evidence of biliary sepsis mean that there is unlikely
to be a single value which can be applied to all patients.
It is useful to consider when PBD is indicated. Jaundiced patients undergoing neoadju-
vant therapy clearly require PBD; if there are major diagnostic delays, though an assessment
of risk of cancer progression must be weighed up against potential risks of surgery in
such cases or if the patient is too frail to undergo surgery. Such patients, however, in
our experience rarely improve significantly after PBD. Cholangitis has been considered
a contraindication for PBD, though in our practice we frequently employ external biliary
drainage, antibiotics, fluid replacement therapy and surgery within the same week if mark-
ers of infection are improving. This has controlled sepsis, avoided complications of PBD
and kept patients within an early surgery pathway. See Table 1. For a summary of potential
indications for PBD and Table 2 for optimizing care should PBD be undertaken.
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Table 1. Absolute and relative indications for Percutaneous biliary drainage (PBD).




If mild, percutaneous external drainage and fluid
replacement may permit early surgery with




If mild, percutaneous external drainage and fluid
replacement may permit early surgery with
trans-sphincteric drainage to reduce the risk
of pancreatitis
Relative
Bilirubin level Exact cut off leve currently unclear, see text.
Delay to surgery Need to consider daily rate if increase in bilirubin as thismay vary from patient to patient
Malnutrition
Ensure exocrine insufficiency corrected and balance
delays to surgery, cancer progression against severity
of malnutrition
Frailty
Frail patients are less likely to tolerate complications of
PBD so a difficult discussion or choice often needs to be
made. For some frail patients, direct to surgery may be
there best chance to have surgery as delays or
complications of PBD can exacerbate frailty
Table 2. Tips for optimising care in the event of PBD requirement.
Indication for PDB Comment
Initial attempt at PBD ERCP with self-expanding metal stent
Position of stent
The stent should be short and ideally not occlude the cystic
duct origin as this can lead to cholecystitis which can delay
surgery or chemotherapy
Periprocedural care
Antibiotics before and after the procedure
Regular observations with escalation to medical team in event
of abdominal pain and/or hypotension. Consideration of CT
in event to exclude pancreatitis or perforation.
Options if initial PBD fails
Maximum of two attempts at ERCP. If unsuccessful for PTC
with stent placement as a rescue option (referral to specialist
centre may be optimal depending on local experience)
Definition of successful PBD
Biliary drainage is defined as successful if the serum bilirubin
level decreased by 50% or more within 2 weeks after
the procedure.
Malnutrition associated with obstructive jaundice and its effects on outcomes follow-
ing surgery is a further area of controversy. In studies by Padillo et al., malnutrition was
more commonly associated with patients older than 68 years and those with high levels of
bilirubin with the suggestion that PBD should be considered to allow alleviation of these
modifiable factors preoperatively [40,41]. However, evidence for the optimal duration of
PBD to improve nutritional status is experimental and its role in malnutrition must be
considered in the broader context of pancreatic exocrine insufficiency [42–45]. Exocrine
insufficiency is prevalent at diagnosis, and although not the sole cause of malnutrition, it is
a major driver of malnutrition and is poorly treated; thus, delays to surgery can exacerbate
malnutrition if PEI is not addressed. A balance must be struck between early surgery and
better treatment of PEI versus correcting jaundice and improving nutrition. A proposed op-
timal pathway would be to provide PERT for all patients and provide early surgery where
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possible; where a patient has a poor performance status with malnutrition, a pathway of
PBD, PERT, and dietician input would be advocated.
2.2. Pancreatic Exocrine Insufficiency and Overcoming Malnutrition to Improve Outcomes
Pancreatic exocrine insufficiency (PEI) and pancreatic enzyme replacement therapy
(PERT) should be considered at all stages of management of pancreatic cancer, it is included
in this section on pre-operative pathways as correct treatment is essential as early in the
care pathway as possible. PEI is far from trivial and should be considered as organ failure.
Untreated failure of other organ systems can be rapidly fatal (for example, renal, cardiac or
respiratory failure or even diabetes) and withholding treatment in these settings is reserved
only for those patients who are on end-of-life pathways. Consequently, it is remarkable that
PEI is underdiagnosed and undertreated. In the authors view, this single issue represents the
simplest pathway improvement in this review and also the intervention with the chance to achieve
most gain.
Addressing pancreatic exocrine insufficiency (PEI) can have an effect upon survival as
strong as that as surgery or chemotherapy and yet many patients remains untreated [46].
A 2016 systematic review of PEI demonstrated a pre-operative prevalence of 44% and a
post-operative prevalence of 74% (for those undergoing pancreatico-duodenectomy for
malignancy). This is likely a conservative estimate owing to the frequent use of faecal
elastase (FE-1) to diagnose PEI (FE-1 has been shown to underestimate PEI following
resection) [47,48]. Furthermore, there is a gradual reduction of exocrine function at a
median value of 10% per month [49]. With the gold standard of testing and longer term
follow up, Lemaire et al. found the post-operative incidence of PEI to be 94% [50]. In
resectable disease the mechanisms underlying PEI are complex and multifactorial. Almost
all physiologic control is lost after pancreatoduodenectomy, and together with other factors
result in insufficient enzymes arriving at the wrong time, to the wrong place and at the
wrong pH for effective function [51,52] (see Figure 1).
Figure 1. Factors contributing to PEI following pancreatico-duodenectomy. *CCK = cholecystokinin.
Symptoms of PEI include pain, bloating, frequency, urgency, diarrhoea, fatty stool,
flatulence, loss of appetite, nausea and vomiting and are physically and mentally dis-
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tressing. The ‘classical’ sign of steathorrhoea is often absent, either because PEI is not
severe enough or because the patient may have unconsciously adopted behaviours to
avoid fat intake [53–55]. PEI is frequently untreated or undertreated worldwide. Studies
from the UK, Europe and Australia demonstrate that only a minority of patients receive
PERT [56–59]. Reasons for under prescribing are multifactorial and may relate to the
lack of an acceptable or accurate routine diagnostic test that can yield results in near real
time [47,60–62]. Confusing symptoms of cancer, weight loss and abdominal discomfort,
further complicate diagnosis.
The consequences of PEI must not be underestimated, these include: weight loss,
malnutrition, micronutrient deficiency, cardiovascular events, osteoporosis, fractures and
sarcopenia [63]. The effect of PEI on operative outcomes is considerable, being associated
with higher rates of post-operative complications, longer hospital stays and increased
costs [64–67].
Pancreatic enzyme replacement therapy (PERT) is cheap, mitigates against weight
loss and improves quality of life. The most compelling argument for PERT is emerging
evidence that it improves survival [46,58,68–71]. Given the failings of diagnostic tests for
PEI and the evident benefits of PERT, it is recommended for all patients with pancreatic
cancer by NICE in the United Kingdom [28].
A healthy pancreas is estimated to produce 900,000 United States Pharmacopeia (USP)
of lipase in response to a meal. Sufficient absorption of fat can be maintained at around
10% of normal capacity, there is thus a need for around 90,000 USP per meal. Given that in
the majority of pancreatic disease some function remains an appropriate starting dose in
resected pancreatic cancer is 75,000 USP with a main meal and 25,000 with a snack [69],
most effective when given across the course of, or just after, a meal rather than before [72].
Co-prescription of a proton pump inhibitor is often required after pancreatoduodenectomy
as a failure to neutralise gastric acid leads to enzymes remaining inactive [73].
Pre-operative malnutrition is associated with significantly poorer post-operative out-
comes for pancreatic resection, addressing this extends beyond just the prescribing of
PERT [74,75]. The international Study Group on Pancreatic Surgery (ISGPS) released a po-
sition paper on nutritional support and therapy in pancreatic surgery, this emphasizes the
importance of pre-operative assessment of nutritional status and recommends nutritional
supplements in those who have, or are at risk of developing, moderate malnutrition [76].
Those with, or at risk of severe malnutrition may benefit from formal nutritional support
with enteral or parenteral feeding [76]. Regular dietician input to asses response, compli-
ance, diet, diabetic optimization, and the potential need for nutritional supplements is
required [77].
Although outside the scope of this article to describe in detail, immunonutrition is
worthy of note. Immunonutrition aims to influence the systemic immune system using
nutritional supplements with immune modulating contents such as arginine, omega-3 fatty
acid and RNA. This is not yet part of routine clinical practice, however, there is evidence
that initiation in the pre-operative period could improve post-operative outcomes [78–81].
The most recent systematic review and meta-analysis of immunonutrition in pancreatic
resection, concluded that immunonutrition reduces infectious complications (especially
wound infection) and length of stay [82].
2.3. Benefits of and Access to Surgical Resection of Pancreatic Cancer in the Elderly
Benefits of resection do not diminish with increasing age [83,84]. Yet, many elderly
patients are considered too frail for surgery and there is significant age-related disparity
in access to surgery. Ageism is a major problem faced by elderly cancer patients; elderly
patients without comorbidity are less likely to receive cancer therapy than younger patients
with comorbidity. Advanced age, in the absence of comorbidity, is mistakenly considered a
more significant barrier to surgery than comorbidity [85]. Elderly patients are less likely
to undergo standard resection, less likely to undergo resection with concomitant venous
resection and less likely to achieve negative margins [86–88]. An American population
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based study of over 45,000 patients with pancreatic adenocarcinoma observed that the rate
of surgery decreased with increasing age: 21% of those under 50, 19% between the age of
50 and 70 and only 13% of those over 70 received surgery [87].
Concerns over risk and perceived lack of benefit of surgery are prohibitive and ac-
count for the discrepancies in care. However, a systematic review of surgery among
elderly patients with pancreatic cancer demonstrated that over time, perioperative mor-
tality has improved for elderly patients following pancreatic resection when compared
to non-elderly patients, with mortality preceding the year 2000 being significantly higher
in elderly patients, but similar from 2000 onwards [86]. Major surgical complications
(post-operative pancreatic fistula, delayed gastric emptying, post pancreatectomy haemor-
rhage and surgical site infections) were similar between the elderly and the non-elderly;
however, respiratory complications did occur more frequently in the elderly population.
Prehabilitation can improve physical functioning and prevent deterioration among patients
whilst waiting for cancer surgery [89–94]. The benefits of surgery are not diminished by
age and therefore older patients with appropriate performance status should not be denied
access based on chronological age alone. Treatment decisions for the elderly should be
made in a multidisciplinary setting, should ideally include the use of a tool such as the
comprehensive geriatric assessment and the input of a geriatrician to avoid discrepancies
in treatment based on chronological age [95,96].
2.4. Prehabilitation
Resection is the only curative option for pancreatic cancer, however, the majority of
patients with a new diagnosis are not suitable for operative management [97]. Baseline func-
tional status influences receipt of curative resection, receipt of adjuvant chemotherapy, the
rate and severity of post-operative complications and long term quality of life [89,98–100].
Functional status is often poor in patients with pancreatic cancer, this is contributed to
by older age at diagnosis, pre-operative sarcopenia, malnutrition and obstructive jaun-
dice [101]. Prehabilitation refers to any interventions, prior to definitive treatment that
are aimed at improving patient health and lifestyle [102]. The concept centres around
pre-operative conditioning to improve nutritional status and aerobic capacity. Studies of
prehabilitation in other types of major surgery have suggested that these programmes
can improve both access to definitive treatment, and post-operative outcomes [103] (See
Table 3). A recent trial randomised patients to standard of care versus standard of care
plus prehabilitation in patients having major abdominal surgery found that the prehabilita-
tion cohort had improved aerobic capacity and a reduction in 30-day readmissions [104].
Unfortunately, systematic reviews and meta-analysis have determined that although pre-
habilitation programmes can potentially improve surgical outcomes, the evidence is weak,
this is most likely do to the variation in prehabilitation regimens and study heterogene-
ity [102,103,105–108].
The majority of evidence for prehabilitation is limited to those undergoing colorectal
resection, hepatic resection or major cardio-thoracic surgery, few studies look specifically
at the impact of prehabilitation in pancreatic resection [109–114] (Table 1). Two studies
have reported on the association between prehabilitation and post-operative outcomes in
pancreatic cancer; Ausania et al. randomised patients to prehabilitation (n = 18) or standard
of care (n = 22). Nakajima et al. compared a cohort of patients undergoing prehabilitation
to historical patients. Neither study determined a significant difference in outcomes except
for reduced rates of delayed gastric emptying in one and a shorter length of stay in the
other. Several studies report an improvement in lean muscle mass prior to surgery and
one reported improvement in quality of life in those undergoing prehabilitation [109–114].
Although showing promising results, the collective interpretation of these studies is difficult
owing to poor standardisation of exercise and nutritional interventions and paucity of
participants. Table 4: Pre-operative areas for potential gain.
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Table 3. Summary of prehabilitation studies for pancreatic resection.
Year Study Design No. Exercise Plan Key Findings
Nakajima et al. 2019 Retrospective,cohort 76
30 days Unsupervised,
self-reported exercise
Shorter length of stay in
prehabilitation group (23 days vs.
days, p = 0.045)
Ausania et al. 2019 Randomisedcontrolled trial 18
2 weeks supervised and
unsupervised, aerobic exercise
Reduction in DGE in prehabilitation
group (5.6% vs. 40.9%, p = 0.01)




No comment on clinical outcomes
Evidence of prehabilitation increasing
tumour vascularity.
Marker et al. 2018 Case series 3
12–16 weeks, supervised,
physiotherapist reported, hour
long, 3× a week
Underpowered
Parker et al. 2018 Prospective,cohort 50
60 min per week unsupervised,
self-reported aerobic and
strengthening exercise
No comment on clinical outcomes
Home based exercise
programme feasible
Ngo-Huang et al. 2019 Prospective,cohort 50
2 weeks, unsupervised,
self-reported, hour long aerobic
exercise
Prehabilitation associated with
improved physical function (6MWT,
STS, GS improved from baseline,
p = 0.48, 0.03 & 0.08, respectively) and
HRQOL (Improved with increased
LPA (p = 0.01)
6MWT = 6 min walk test, STS = Sit to stand, GS = Gait speed, HRQOL = Health Related Quality of Life, LPA = Light physical activity.
Table 4. Pre-operative areas for potential gain.
Areas for Gain




- PBD related complications
are common
- Avoidable delay to surgery







- Increase number of patients
undergoing curative surgery
- Improve overall survival
Correction of PEI related
malnutrition
- PEI is highly prevalent and
related to weight loss, reduced
QoL, reduced survival
- Under-prescribing of PERT
- Inadequate dosing
- Malnourished at baseline
- Sarcopenia
- PERT prescribing for all





- Improve quality of life




- Older age group
- Sarcopenia
- Too ‘frail’ for treatment
- Deconditioning
- Consider who is ‘at risk’
- Physiotherapy involvement
- More research
- Potential to reduce
some complications
- Reduce length of stay
- Potential to improve access
to treatment
Old age/frailty
- Nihilistic attitudes towards
older age
- Elderly not receiving same
standard of care despite proven
benefit
- MDT decision making with
geriatrician if able
- Use of assessment tools.
Such as CGA
- Co-morbidities rather than
chronological age as
deciding factor.
- Improved access to curative
treatment options for
the elderly.
PEI = Pancreatic exocrine insufficiency, PBD = Pre-operative biliary drainage, QoL = Quality of life, PERT = Pancreatic enzyme replacement
therapy, PPI = Proton pump inhibitor, CGA = Comprehensive geriatric assessment.
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3. Peri-Operative Pathways
3.1. Enhanced Recovery after Surgery
Enhanced recovery after surgery (ERAS) is a multimodal approach to a patient’s
perioperative journey which aims to facilitate early return to the preoperative state [115].
Broadly, it facilitates sustained recovery and reduces complications. A secondary benefit is
frequently a reduced length of stay.
The value of ERAS pathways in pancreatic surgery has been recommended on the
basis of high level evidence in domains such as avoidance of hypothermia, use of wound
catheters compared to epidural analgesia (EDA), use of somatostatin analogues to reduce
CR-POPF [116]. protocols for thromboprophylaxis and antimicrobials and interventions
for preoperative nutrition for patients with severe weight loss [36]. As patient reported
outcomes (PROs) have become of particular importance in pancreatic cancer due to the
elderly cohort of patients, a recent addition has been patient-centred PROs into the ERAS
pathway [117,118].
The degree of compliance with ERAS pathways is strongly associated with clinical
outcome [119]. With numerous components, intensive monitoring of the pathway with
regular audit and a dedicated specialist nurse input improves compliance. An evaluation
into the feasibility of an ERAS pathway after PD has demonstrated over 70% compliance
achieved within a multicentre cohort study and was associated with a significant reduction
of overall complications and length of stay [120].
ERAS after pancreatic surgery have been associated with a reduction in mild com-
plications (Clavien Dindo grade I-II) significant improvements in overall morbidity and
length of stay without any increase in readmission [121–125]. Effect on pancreatic specific
complications is difficult to interpret as studies have variably included PD and distal
pancreatectomy and ISGPS definitions have not been consistently reported for delayed
gastric emptying (DGE) and postoperative pancreatic fistula (POPF) However, a lower
incidence of DGE has been observed with no effect on POPF rate [122,123,125].
Implementation of ERAS pathways has been hindered due to the economic impact
associated with the necessary resources required, namely a specialist nurse, audit and data
collection and patient information booklets [126]. However, these costs, have been offset by
the reduction in postoperative complications and subsequent hospital length of stay [127].
Though the short-term benefits are evident, long term benefits have also been sug-
gested by one study where a relationship between increased compliance to the ERAS
pathway and survival benefit has been found [128].
3.2. Reducing Complications from Surgery
Surgery alone, is a poor treatment for pancreatic cancer. Only with associated receipt
of chemotherapy do patients gain a good chance for cure. One major barrier to patients re-
ceiving adjuvant therapy is the occurrence of post-operative complications. Thus, strategies
to reduce these are attractive not only to improve perioperative outcomes but improve the
delivery of adjuvant therapy. Post-operative pancreatic fistula (POPF) is the most frequent
and severe complication after surgery [129]. Presently there is no widely accepted approach
to reducing rates of clinically relevant POPF but a national study of early detection and
minimally invasive treatment of POPF aims to determine whether the severity of POPF
can be reduced [130].
An individual patient’s risk of POPF varies hugely. It is somewhat remarkable that
POPF rates are not routinely adjusted to take this into account. Individual surgeons
risk adjustment and CUSUM analysis is a way for surgeons to objectively assess their
outcomes [131]. Such strategies could help inform surgeons of optimal techniques.
Strategies to improve outcomes after complex procedures such as pancreatoduo-
denectomy, evolve from a critical understanding of events and outcomes. Without critical
analysis background noise, variations in practice and organisational differences can make
this task insensitive. Determining the root causes of mortality after pancreatectomy demon-
strates this well [129]. Only by conducting in depth analyses of processes and outcomes
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can surgeons begin to understand fundamental reasons for failure. Solutions can then be
developed which are designed to overcome problems which are prevalent at the local level.
Solutions are likely to vary from centre to centre dependent upon variation in practice
and outcome.
A further key improvement is to determine benchmarks of optimal outcomes. This
strategy seeks to reduce the effect of variation in practice between centres by focussing
on common factors between centres and avoiding outlier cases. In pancreatic cancer, this
has allowed teams to compare outcomes to those of their peers after surgery for resectable
cancer or with associated venous resection [132,133].
Taking the concept of assimilated gains, the Dutch are leading the way with a na-
tionwide implementation of best practices based upon critical analysis of pathways and
suboptimal outcomes with the PACAP-1 trial which seeks to improve outcomes and overall
survival [134]. Table 5: Summary of Peri-operative areas for gain
Table 5. Summary of Peri-operative areas for gain.
Areas for Gain






based upon best evidence
- Routine audit
- Reduced complications






- Root cause analysis




- Benchmarking and root
cause analysis demonstrate
where local outcomes fall





- Improved access to
adjuvant chemotherapy




- See Table 2
- Junior Dr education
- Patient education
- PERT prescribing check
- Dietetic review
- See Table 4
- See Table 4
ERAS = Enhanced Recovery after Surgery, QI = Quality Improvement, POPF = Post-Operative Pancreatic Fistula, LoS = Length of Stay,
PERT = Pancreatic Exocrine Replacement Therapy.
4. Post-Operative Pathways
Post-operative strategies should be designed to enhance functional recovery, maximise
uptake of adjuvant chemotherapy and delivering appropriate surveillance. Care should be
continuous and multidisciplinary, with continued nutritional consideration (as outlined in
the pre-operative section). Functional decline and lack of chemotherapy uptake is more
pronounced in elderly.
4.1. Adjuvant Therapy in Resectable Pancreatic Cancer
The benefit for adjuvant therapy is without question. Alone surgery achieves cure in
less than 10% of patients [3,135]. Currently, a multimodal approach is the standard of care
where 6 months of mFOLFIRINOX based on the results of PRODIGE-24 RCT for those with
a sufficient performance status, or a combination of gemcitabine and capecitabine based
on ESPAC-4 RCT [136,137]. Patients not sufficiently fit for combination therapy may still
benefit from gemcitabine. The role of adjuvant therapy following neoadjuvant therapy and
resection, however, is less clear. A recent multi-centre international study demonstrated
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that adjuvant chemotherapy following NAT, was only of benefit among patients with node
positive disease [138].
Widespread variation in the use of adjuvant therapy is clear between and within
countries. For example, studies demonstrate that 51% of patients receive adjuvant therapy
in the USA, 54% in the Netherlands, 66% in Japan and 74% in Canada. Widespread varia-
tion within countries is also evident [139–142]. Within the Netherlands, rates of adjuvant
therapy varied from 26 to 74% between health care providers. Sociodemographic varia-
tion explains some variation with deprived patients less likely to receive therapy [143].
Advanced age is a common factor associated with underuse of adjuvant therapy and will
be considered separately below. However, such wide differences cannot be explained by
demographic differences alone. Such data clearly points at systematic variation. Such
variation is clearly undesirable and yet, despite the clear advantage of adjuvant therapy,
there is little emphasis upon ensuring that patients chances of receiving therapy are op-
timized [144]. This low completion rate of the full therapeutic sequence may in part be
explained by the reticence to initiate adjuvant chemotherapy following postoperative
complications or poor performance status. However, ESPAC-3 has addressed this issue
of time to initiate and optimal duration of chemotherapy [145]. Within this study, 68% of
patients completed all six cycles of chemotherapy and for these patients, overall survival
was significantly favoured. In those who did complete therapy, there was no difference in
survival when comparing those who started earlier than eight weeks compared to those
who started between 8 and 12 weeks, therefore time to initiation of chemotherapy was an
important prognostic factor in favour of later treatment. Thus, this study concluded that
completion of chemotherapy rather than early initiation was more important for survival.
Centralised cancer surgery is widely practiced. However, centralised chemotherapy is
not standard practice. There is evidence that concentrating adjuvant therapy to a dedicated
regional service increases the proportion of patients that receive therapy [146]. Overcoming
nihilistic views and patients fear of therapy are important strategies as many patients
choose not to pursue chemotherapy and clinicians not referring patients for chemotherapy
is a mindset in great need of change [147].
A further variable that must be considered is not simply whether a patient receives
adjuvant therapy but that efforts must focus upon an individualised approach where
patients receive a regime that is as strong as can be tolerated for that individual. Incremental
gains of multiagent therapy are seen over single agent gemcitabine [3,135,137]. Yet, there is
very little data upon strategies to optimise not just the delivery of adjuvant therapy but
also the regimen that is delivered. Some evidence supports centralised care to deliver more
multiagent therapy [147].
Liquid biopsies are a novel way to diagnose cancer at an early stage, aid in prognostic
evaluation [148], determine targets for therapy [149] and to evaluate cancer recurrence
after treatment. The technique involves determining cancer DNA, vesicles and tumour
cells in circulating blood [150,151]. Nomograms can be used to stratify patient risk for
selection to treatment and may influence the choice of NAT, surgery or nature of adjuvant
chemotherapy [152–156].
4.2. Benefits of and Access to Chemotherapy in the Elderly Population
After resection of pancreatic cancer, disease free survival (DFS) and disease specific
survival (DSS) appear similar between elderly and younger patients, but overall survival
(OS) is shorter, a possible reflection that elderly patients are less likely to receive adjuvant
chemotherapy [86,157–159]. Elderly patients have just as much benefit from adjuvant
therapy as younger patients and when chemotherapy use is stratified between young and
older patients overall survival is the same [160]. The CONKO-001 trial had no upper age
limit and specifically demonstrated that those over 65 show a similar improvement in OS
and DFS as have numerous other studies evaluating adjuvant chemotherapy for pancreatic
cancer [137,159,161–163]. This benefit is maintained when considering more aggressive
regimens in the elderly such as FOLFIRINOX or neo-adjuvant chemotherapy [164–166].
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Consequently, strategies to increase the use of chemotherapy in the elderly, such as central-
isation of oncology services and measures to address frailty, yield major benefits [146,167].
The comprehensive geriatric assessment (CGA) is recommended by the Society for Inter-
national Oncology in Geriatrics as a useful decision making tool for older people with
malignancy [168]. There are several studies suggesting that the CGA can be useful in
predicting functional decline, toxicity and overall survival [169,170] The CGA is lengthy
and time consuming, a more practical approach, as recommended by the National Compre-
hensive Cancer Network, the European Organisation for Research and Treatment of Cancer
and the International Society of Geriatric Oncology is to use a short frailty screening tool
(such as the Fried score, the Clinical Frailty Scale or the Geriatric 8) to identify those who
require a full screening [171–177].
Like surgery, the benefits of chemotherapy are not lessened by age and therefore older
patients with appropriate performance status should not be denied access. Treatment
decisions should be made in a multidisciplinary setting and include the use of a frailty
screening tool and the input of a geriatrician to avoid discrepancies in treatment based on
chronological age [95,96].
Since there are no published accepted standards for the proportion of patients that
receive adjuvant therapy after pancreatic cancer surgery there is lack of clarity about what
is acceptable practice. Thus, local audit and benchmarking one’s practice against peers is
an essential step in the standardisation of practices. Quality improvement programs could
further enhance delivery of adjuvant chemotherapy if they were to target those patients
most at risk of not receiving therapy, i.e., to overcome barriers presented by age, frailty and
good functional recovery after surgery.
4.3. Surveillance after Resection of Pancreatic Cancer
Surveillance after resection of other cancer types is routine and evidence based. The
notion is simple, that early detection of recurrence is more likely to identify disease at an
earlier asymptomatic phase when patients are more likely to have preserved performance
status and ultimately more likely to receive treatment. Most guidelines, including those
from the European Society for Medical Oncology (ESMO) and International Association
of Pancreatology/European Pancreatic Club (IAP/EPC), do not recommend routine
surveillance after pancreatic cancer resection due to the poor prognosis and limited
treatment options available for recurrence [178,179]. The nature of surveillance protocols
typically involve CT scans at 3 or 6 month intervals supplemented by CA19-9 analysis.
The optimal interval and impact of surveillance programs remain to be seen. It may be
that artificial intelligence may help refine and improve surveillance programs; there is
currently much interest in AI as a tool to facilitate the diagnosis of breast cancer within
screening programs.
In the setting of recurrent pancreatic cancer there are an increasing number of treat-
ment strategies. Despite this, many patients fail to receive palliative therapy. However,
an individualised approach to treating recurrent pancreatic cancer is logical. Around
half of all patients recur with local only disease [180]. Whilst systemic therapy seeks
to control occult metastatic disease local therapies in the form of high intensity radio-
therapy or ablation can be delivered [181]. Given that many patients are elderly, frail
or may have had poor experience with systemic therapy local therapy can be delivered
with more less disruption and more satisfaction for the patient. Targeted therapy of
oligometastatic disease also offers alternative options for a limited number of patients.
Furthermore, surveillance is desired by patients and clinicians alike [182,183]. Table 6:
Areas for Post-operative gain.
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Table 6. Areas for Post-operative gain.
Areas for Gain






- Establish standards of
practice and benchmarks for
the proportion of patients
that receive
adjuvant therapy
- QI programs to address
frailty, advanced age and
recovery after surgery










- Improved detection of
early recurrence
- Improved treatment rates
- Improved duration
of survival
Nutrition - See Table 4
- Education of local
physicians and those in
palliative care
- See Table 4
- See Table 4
QI = Quality improvement.
5. Novel Areas for Review
Though this body of work focusses upon areas where benefit can be clearly derived
using existing evidence base there are areas with an emerging evidence base where benefit
may be derived if practices are adopted.
Pancreatic surgery is associated with a high rate of cancer recurrence. Improving the
staging pathways and novel approaches to treatment of the surgical margin are ways to
improve outcomes.
Early cancer recurrence, even within ninety days of surgery, has to be considered
a failure of staging [129]. The addition of routine Positron Emission Topography (PET)
or Magnetic resonance imaging (MRI) scanning can help detect occult cancer. PET scan-
ning, within a randomised trial, upstaged 20% of patients, preventing futile surgery [184].
However, it is important to note that the routine use of PET-CT is still debatable as it
cause delays to resection and the potentially false positive results that may erroneously
prevent surgery [185,186]. MRI can upstage 10–24% of patients with occult liver metastases
where diffusion weight images can identify lesions under 5 mm, being more sensitive than
computerised tomography (CT) or PET-CT [187–189]. These tests need to be considered
carefully, however, as false positive results can be caused by common scenarios such as
abscesses secondary to cholangitis and can delay treatment.
Failure of surgery to clear the margin is an Achilles heel of pancreatoduodenectomy.
Local recurrence is very high after surgery, positive margins are associated with reduced
survival and therefore it is necessary to consider how outcomes can be improved [190,191].
Neoadjuvant therapy (NAT) is associated with a higher rate of R0 resections, though it is
important to consider results on an intention to treat basis [192,193]. There is much interest
in NAT for resectable pancreatic cancer. Ongoing clinical trials will help determine the
evidence base for this treatment. There are many retrospective cohort studies which are at
risk of various bias including selection and survivor bias and until well conducted trial
data is available it is not possible to make a clear statement [194]. Intraoperative frozen
section has been used to identify positive pancreatic transection margins and the role of
extending resections has been explored in numerous studies, but systematic review fails
to observe a benefit to this practice [193]. Similarly, extending lymphadenectomy is not
associated with greater survival but with morbidity [195,196]. The standard approach to
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pancreatoduodenectomy leaves perineural tissue around the superior mesenteric artery.
It is this margin which is most frequently positive on histologic analysis. An artery
first approach has a theoretical advantage that it can clear periadventitial tissues but
clinical studies fail to demonstrate benefit in terms of improving R0 margin status [197,198].
Intraoperative radiotherapy has been long considered as an adjunct to improving margin
status but no high-level evidence yet exists [199]. The addition of stereotactic ablative
radiotherapy within a NAT program does not appear to improve R0 rates [200]. Irreversible
electroporation has gained interest, predominantly surrounding control of locally advanced
pancreatic cancer though the technology could be applied to improve margin control
at resectable cancer. However, concerns over safety and a lack of high level evidence
remain [201]. There is thus much work to be done in this area and focussing efforts on the
problem of the surgical margin could reduce local recurrence.
Peritoneal metastases are less common than local recurrent or liver metastases but
when they occur are associated with very poor outcomes. Positive intraoperative peritoneal
cytology correlates with poor oncologic outcomes, in the absence of visible metastatic
disease [202]. Among patients with cytology positive, or even macroscopic peritoneal
disease, intraperitoneal chemotherapy can control ascites and some patients can go on to
achieve surgical resection [203,204]. Such experience is limited to Japan. The remarkable
outcomes indicate a potential role for intraperitoneal therapy, challenge current beliefs
about pancreatic cancer biology and prognosis and merit a wider review.
Personalised medicine in pancreatic cancer care is most strongly associated with defin-
ing an individual’s cancer genetics. Large multinational, multicentre organisations/trials
are ongoing such as precisionpanc (https://precisionpanc.org, accessed on 10 January
2021). There have, however, been many negative trials of genetic targets among patients
with metastatic pancreatic cancer which include MEK inhibitors, IGFR inhibitors, mTOR in-
hibitors, TRK inhibitors, NOTCH inhibitors, TGF-β inhibitors, immunotherapy or vaccine
therapy [205]. Established genetic targets in resectable pancreatic cancer are thus largely
unclear; the most actionable mutation is BRCA1-2 which is identified in approximately 5%
of patients [206]. Patients with these tumours are sensitive to platinum agents and thus
will be treated by inclusion of oxaliplatin in therapy regimens [207]. This target has also
been exploited by the PARP inhibitor Olaparib [208].
6. Conclusions
This review sought to elucidate key areas of variation, undertreatment and pathway
changes where improvements can be realised with little effort. Novel therapeutic options
will present themselves in the future, but it would be remiss of any team caring for
this cohort of patients to inadequately utilise current evidence and implement optimal
treatment pathways. There is a disconnect between funding for research to establish novel
treatments far outstripping funding to implement best care at the level of the health care
provider/organisation. It is essential that surgeons understand that surgery is just one part
of a complex pathway and that they are ideally placed to act as change agents to optimise
broader pathway improvements. Some changes can be clearly applied to the majority, if
not all patients, such as PERT among those undergoing pancreatoduodenectomy. Other
interventions can never be applied to all patients. There will always be some jaundiced
patients with resectable cancer that undergo PBD or some patients who never receive
adjuvant therapy. Locally, nationally or internationally accepted benchmarks are required
to understand what is achievable and to help teams identify areas of poor performance.
Collaborative multicentre, multinational studies are an essential part of assessing and
improving patient care in the 21st century and teams are encouraged to develop and take
part in these ventures. Through the aggregation of marginal gains, our patients can realise
better outcomes and experience in the near future.
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